secukinumab + placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Psoriasis, Plaque-type Psoriasis

Conditions

Psoriasis, Plaque-type Psoriasis

Trial Timeline

Jan 1, 2012 → Dec 1, 2014

NCT ID

NCT01537432

About secukinumab + placebo

secukinumab + placebo is a phase 2 stage product being developed by Novartis for Psoriasis, Plaque-type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01537432. Target conditions include Psoriasis, Plaque-type Psoriasis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05722522	Phase 3	Terminated	Aug 10, 2023	Dec 13, 2024	Rotator Cuff Tendinopathy
NCT05758415	Phase 3	Terminated	Aug 2, 2023	Dec 11, 2024	Rotator Cuff Tendinopathy
NCT04737330	Phase 3	Terminated	Nov 29, 2021	May 16, 2023	Thyroid Eye Disease
NCT04732117	Phase 3	Completed	Jul 21, 2021	Feb 14, 2025	Non-radiographic Axial Spondyloarthritis
NCT04181762	Phase 3	Terminated	Jul 7, 2020	Sep 13, 2023	Lupus Nephritis
NCT04156620	Phase 3	Completed	Dec 11, 2019	Dec 20, 2022	Ankylosing Spondylitis
NCT03713632	Phase 3	Completed	Feb 25, 2019	Jul 19, 2022	Hidradenitis Suppurativa
NCT03713619	Phase 3	Completed	Jan 31, 2019	Jul 26, 2022	Hidradenitis Suppurativa
NCT03055494	Approved	Completed	Apr 18, 2017	Feb 26, 2019	Plaque Psoriasis
NCT02896127	Phase 3	Completed	Oct 18, 2016	Mar 19, 2019	Ankylosing Spondyloarthritis
NCT02696031	Phase 3	Completed	Apr 29, 2016	Mar 11, 2021	Non-radiographic Spondyloarthritis
NCT02599129	Phase 2	Terminated	Nov 1, 2015	Nov 1, 2016	Alopecia Areata
NCT02594098	Phase 2	Completed	Nov 1, 2015	Jan 30, 2018	Atopic Dermatitis
NCT02362789	Phase 3	Completed	Jan 4, 2015	Jul 15, 2016	Psoriasis
NCT01989468	Phase 3	Completed	Apr 10, 2014	Mar 28, 2018	Psoriatic Arthritis
NCT02044848	Phase 2	Terminated	Feb 1, 2014	Sep 1, 2014	Type 1 Diabetes Mellitus
NCT01892436	Phase 3	Completed	Sep 30, 2013	Jan 11, 2018	Psoriatic Arthritis
NCT01807520	Phase 3	Completed	Jun 20, 2013	Jan 3, 2017	Moderate to Severe Nail Psoriasis
NCT01537432	Phase 2	Completed	Jan 1, 2012	Dec 1, 2014	Psoriasis, Plaque-type Psoriasis

Competing Products

20 competing products in Psoriasis, Plaque-type Psoriasis

See all competitors

Product	Company	Stage	Hype Score
Ixekizumab + Placebo	Eli Lilly	Phase 2	52
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo	Ventyx Biosciences	Phase 2	47
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous	Eli Lilly	Phase 2	52
Ixekizumab	Eli Lilly	Phase 3	77
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo	Eli Lilly	Phase 3	77
Placebo + Baricitinib	Eli Lilly	Phase 2	52
CT-P43 + Stelara	Celltrion	Phase 3	77
CT-P17 + EU-approved Humira	Celltrion	Phase 3	77
CT-P55 + EU-approved Cosentyx	Celltrion	Phase 3	77
AMG 139	AstraZeneca	Phase 1	33
alefacept + polyvalent pneumococcal vaccine	Astellas Pharma	Approved	85
alefacept	Astellas Pharma	Phase 2	52
Tacrolimus Cream	Astellas Pharma	Phase 3	77
alefacept	Astellas Pharma	Phase 3	77
peficitinib + Placebo	Astellas Pharma	Phase 2	52
Alefacept	Astellas Pharma	Phase 3	77
Amevive exposure	Astellas Pharma	Pre-clinical	23
alefacept + placebo	Astellas Pharma	Phase 3	77
alefacept	Astellas Pharma	Approved	85
ASKP1240 + Placebo	Astellas Pharma	Phase 2	52

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved